Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.